Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
